Approval · Notice of Compliance 14202 · 2013
STIVARGA: Notice of Compliance 14202
Issued March 11, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14202
- Date
- March 11, 2013
- Company
- Bayer Inc.Elkhart, Indiana, United States
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Multikinase inhibitor; antineoplastic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| STIVARGA | 02403390 | Marketed |
Medicinal ingredients
- REGORAFENIB 40 MG per TAB